Shortlist by what you need
Start here if you know why you are leaving Paige.
Want the closest match?
PathAIMost similar to Paige in what it does, its category and its price.
Visit (opens PathAI in a new tab)Want the best rated?
ArteraRated 4.4 out of 5 in our review, against 4.1 for Paige.
Visit (opens Artera in a new tab)
At a glance
Green means better than Paige, red means worse. Prices are starting prices per month.
| Tool | Our rating | Starts at | Free plan | Best for | Compare |
|---|---|---|---|---|---|
 PaigeBaseline | 4.1 | Not listed | No | Digital pathology AI co-pilot from Memorial Sloan Kettering researchers, acquired by Tempus in 2025 | |
| PathAI | 4.3+0.2 | Not listed | No | First AI pathology platform FDA-cleared for primary diagnosis, now deployed nationwide via Labcorp | vs Paige |
 Bioptimus | 4.2+0.1 | Not listed | No | Foundation models for biology spanning molecular, cellular and tissue scales | vs Paige |
 Proscia | 4.3+0.2 | Not listed | No | FDA-cleared digital pathology platform for primary diagnosis and biomarker research. | vs Paige |
 Rayscape | 3.7−0.4 | Not listed | No | FDA-cleared AI that reads chest X-rays and lung CTs for 148+ pathologies, trained on 42M+ medical images - detects, measures, and tracks pulmonary nodules from 3 to 30mm. | vs Paige |
| Artera | 4.4+0.3 | Not listed | No | FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions. | vs Paige |
 Triomics | 4.0−0.1 | Not listed | No | AI for oncology workflows, supporting clinical trial matching and cancer care decisions. | vs Paige |
 SOPHiA GENETICS | 3.9−0.2 | Not listed | No | AI genomic analytics at 98-99% accuracy, deployed across 1,000+ healthcare institutions in 75+ countries - 2.6 million-plus genomic profiles analyzed to date. | vs Paige |
 Tempus AI | 4.3+0.2 | Not listed | No | Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue | vs Paige |
The alternatives in detail
In order of how closely each one matches Paige.
PathAI
4.3Not listed
vs Paige+0.2
First AI pathology platform FDA-cleared for primary diagnosis, now deployed nationwide via Labcorp.
- AISight Dx analyzes digital pathology slide images to assist diagnosis
- FDA 510(k) clearance for primary diagnosis in clinical settings, June 2025
- Predetermined Change Control Plan allows faster future software updates
Genuine FDA clearance for primary diagnosis, not just an assistive tool
Enterprise quote-based pricing requires a sales conversation, no published rates
Bioptimus
4.2Not listed
vs Paige+0.1
Foundation models for biology spanning molecular, cellular and tissue scales.
- Foundation models trained across molecular, cellular and tissue scales
- Digital pathology models for research and trial workflows
- Transfer learning that reuses existing imaging and omics archives
Cross-scale model design rather than one narrow task classifier
Requires in-house validation on local cohorts before clinical reliance
Proscia
4.3Not listed
vs Paige+0.2
FDA-cleared digital pathology platform for primary diagnosis and biomarker research.
- FDA-cleared for primary clinical diagnosis in AP-Dx
- Concentriq AP, AP-Dx and LS configurations
- Biomarker research and clinical trial workflows
FDA clearance for primary diagnosis, not just research viewing
No published pricing
Rayscape
3.7Not listed
vs Paige−0.4
FDA-cleared AI that reads chest X-rays and lung CTs for 148+ pathologies, trained on 42M+ medical images - detects, measures, and tracks pulmonary nodules from 3 to 30mm.
- 148+ pathology detection on chest X-rays
- Pulmonary nodule detection, measurement, and tracking on lung CT
- Multiple FDA clearances and extensive clinical validation
Genuine regulatory clearance (FDA) rather than just a marketing claim
Pricing isn't public - requires direct institutional engagement
Artera
4.4Not listed
vs Paige+0.3
FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions.
- Multimodal AI trained on digitized biopsy images paired with clinical data
- FDA De Novo authorization for the ArteraAI Prostate Test
- FDA clearance for ArteraAI Breast digital pathology risk stratification
Regulatory clearance (FDA De Novo, NCCN guideline inclusion) beyond most AI health startups
Not a self-serve software product; access runs through labs, clinicians, and insurance billing
Triomics
4.0Not listed
vs Paige−0.1
AI for oncology workflows, supporting clinical trial matching and cancer care decisions.
- AI built specifically for oncology rather than general medicine
- Clinical trial matching against unstructured patient records
- Structuring of oncology data for downstream decision support
Trial matching addresses a real and higher-priced manual bottleneck
Clinical deployment requires validation and governance review
SOPHiA GENETICS
3.9Not listed
vs Paige−0.2
AI genomic analytics at 98-99% accuracy, deployed across 1,000+ healthcare institutions in 75+ countries - 2.6 million-plus genomic profiles analyzed to date.
- SOPHiA DDM - AI genomic and radiomic analysis platform
- 98-99% accuracy across 2.6M+ analyzed genomic profiles
- Oncology coverage - solid tumors, blood cancers, hereditary cancers, liquid biopsy
Accuracy claims are backed by scale (2.6M+ profiles), not a small validation sample
No published pricing - an institutional sales process
Tempus AI
4.3Not listed
vs Paige+0.2
Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue.
- Machine learning applied to genomic and clinical data for precision treatment matching
- One of the largest connected libraries of clinical and molecular data
- Publicly traded on Nasdaq under the ticker TEM
Publicly reported financials give unusual transparency into scale and growth
Pricing runs through insurance billing and enterprise agreements, not published rates
FAQ
Questions people ask
Is Paige free?
Paige does not list a free plan. Check its pricing page for current plans.
How did you pick these alternatives?
We match tools on what they do, their category and their price, using the details in our directory. Ratings come from our reviews and reader reviews.